• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.T细胞介导的免疫抑制是P815肥大细胞瘤及其转移灶过继性免疫治疗的障碍。
J Exp Med. 1981 Oct 1;154(4):1033-42. doi: 10.1084/jem.154.4.1033.
2
Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.介导和抑制已建立肿瘤的过继性免疫疗法的T细胞的特异性。
J Leukoc Biol. 1984 Jul;36(1):27-37. doi: 10.1002/jlb.36.1.27.
3
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.环磷酰胺辅助的已建立肿瘤的过继性免疫疗法取决于肿瘤诱导的抑制性T细胞的清除。
J Exp Med. 1982 Apr 1;155(4):1063-74. doi: 10.1084/jem.155.4.1063.
4
Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.针对已形成肿瘤的被动转移免疫的表达取决于受体中细胞溶解性T细胞的产生。受抑制性T细胞的抑制。
J Exp Med. 1983 May 1;157(5):1448-60. doi: 10.1084/jem.157.5.1448.
5
Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.在P815肥大细胞瘤进行性生长过程中,Ly 1+2-抑制性T细胞下调Ly 1-2+效应性T细胞的生成。
Immunology. 1985 Jan;54(1):47-56.
6
Adoptive immunotherapy of established tumors. Acquisition of radioresistance by tumor-specific T cells after passive transfer into tumor-bearing recipients.已建立肿瘤的过继性免疫疗法。肿瘤特异性T细胞被动转移至荷瘤受体后获得放射抗性。
Int J Cancer. 1994 May 15;57(4):592-7. doi: 10.1002/ijc.2910570425.
7
The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.伴随抗肿瘤免疫的抗转移功能。II. Ly-1+2+效应T细胞的产生会暂时导致已播散肿瘤细胞破坏的证据。
J Immunol. 1986 Feb 15;136(4):1510-5.
8
Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.由于变异细胞的存活和增殖导致特异性过继性免疫治疗失败。
Cancer Immunol Immunother. 1989;28(4):241-7. doi: 10.1007/BF00205232.
9
Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.对进行性纤维肉瘤免疫反应的产生与衰退。I. Ly-1+2-抑制性T细胞下调Ly-1-2+效应性T细胞的产生。
J Exp Med. 1984 May 1;159(5):1295-311. doi: 10.1084/jem.159.5.1295.
10
Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.抗雌激素通过细胞毒性T淋巴细胞增强P815小鼠肥大细胞瘤的免疫治疗。
Anticancer Res. 1997 Mar-Apr;17(2A):1083-8.

引用本文的文献

1
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care.过继性细胞疗法治疗实体瘤:迈向个体化标准治疗之路。
Cells. 2021 Apr 5;10(4):808. doi: 10.3390/cells10040808.
2
A pharmacologic perspective on newly emerging T-cell manipulation technologies.新兴 T 细胞操控技术的药理学视角。
Br J Clin Pharmacol. 2013 Aug;76(2):173-87. doi: 10.1111/j.1365-2125.2012.04475.x.
3
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.摆脱抑制:干细胞移植后肿瘤特异性效应细胞胜过调节性T细胞。
Blood. 2008 Feb 15;111(4):2112-21. doi: 10.1182/blood-2007-06-096586. Epub 2007 Dec 6.
4
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.免疫治疗逃逸:影响肿瘤消退/进展的可能机制
Cancer Immunol Immunother. 2004 Oct;53(10):844-54. doi: 10.1007/s00262-004-0540-x. Epub 2004 Jun 10.
5
HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity.与外周血淋巴细胞共培养的HeLa细胞通过上调吲哚胺2,3-双加氧酶活性获得免疫抑制表型。
Immunology. 2002 Apr;105(4):478-87. doi: 10.1046/j.1365-2567.2002.01390.x.
6
Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.荷瘤状态下抗肿瘤T细胞反应的调节机制。
Immunol Res. 1995;14(4):271-91. doi: 10.1007/BF02935625.
7
Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.转化生长因子-β(TGF-β)介导的荷瘤状态下的免疫抑制:TGF-β产生增加以及抗肿瘤CD4+ T细胞功能对TGF-β的敏感性逐渐增强。
Jpn J Cancer Res. 1993 Mar;84(3):315-25. doi: 10.1111/j.1349-7006.1993.tb02873.x.
8
Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor.香菇多糖在裸鼠体内抗肿瘤作用的重建:CD4阳性T细胞克隆引发的迟发型超敏反应在效应细胞浸润肿瘤中的作用。
Jpn J Cancer Res. 1994 Apr;85(4):409-17. doi: 10.1111/j.1349-7006.1994.tb02374.x.
9
Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.通过减轻肿瘤负荷,恢复在荷瘤状态下受到抑制的抗肿瘤CD4+ T细胞反应性。
J Cancer Res Clin Oncol. 1994;120(5):279-85. doi: 10.1007/BF01236384.
10
Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.结肠癌的进展机制:可溶性白细胞介素-2(IL-2)受体、IL-2加抗CD3增殖反应与肿瘤分期的相关性
Cancer Immunol Immunother. 1994 Mar;38(3):160-6. doi: 10.1007/BF01525636.

本文引用的文献

1
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.T细胞介导的抗肿瘤免疫抑制。免疫原性肿瘤进行性生长的一种解释。
J Exp Med. 1980 Jan 1;151(1):69-80. doi: 10.1084/jem.151.1.69.
2
In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.体外诱导对同基因肥大细胞瘤的细胞毒性及其被荷瘤小鼠的脾细胞和胸腺细胞抑制的情况。
J Immunol. 1976 Feb;116(2):288-93.
3
Passive immunotherapy of cancer in animals and man.
Adv Cancer Res. 1977;25:323-88. doi: 10.1016/s0065-230x(08)60637-5.
4
Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice.T细胞集之间的免疫调节回路。II. 体内反馈抑制的生理作用:NZB小鼠中不存在。
J Exp Med. 1978 Apr 1;147(4):1116-25. doi: 10.1084/jem.147.4.1116.
5
In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma.通过特定效应细胞在体内消除已建立的同基因大鼠莫洛尼病毒诱导的肉瘤。
J Immunol. 1979 Oct;123(4):1772-7.
6
Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen.1-氟-2,4-二硝基苯免疫T细胞的活性抑制。抗原诱导辅助性T细胞的需求。
J Exp Med. 1979 May 1;149(5):1197-207. doi: 10.1084/jem.149.5.1197.

T细胞介导的免疫抑制是P815肥大细胞瘤及其转移灶过继性免疫治疗的障碍。

T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

作者信息

Dye E S, North R J

出版信息

J Exp Med. 1981 Oct 1;154(4):1033-42. doi: 10.1084/jem.154.4.1033.

DOI:10.1084/jem.154.4.1033
PMID:6457075
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2186481/
Abstract

Progressive growth of the P815 mastocytoma in semisyngeneic mice evokes the generation of a T cell-mediated mechanism of immunosuppression that inhibits the capacity of passively transferred, tumor-sensitized T cells from regressing this tumor in recipient mice. This conclusion is based on two findings: (a) that it is possible to demonstrate adoptive T cell-mediated regression of established tumors, but only if the tumors are growing in T cell-deficient recipients, and (b) that adoptive T cell-mediated regression of tumors in these recipients can be inhibited by the infusion of splenic T cells from T cell-intact, tumor-bearing donors. The results of additional experiments designed to measure the effect of decreasing the number of suppressor cells and the time that they are infused, relative immune cells, indicate that the function of suppressor cells in this model is to inhibit the replication of passively transferred immune T cells. The results obtained with the P815 mastocytoma are similar to those obtained previously with a chemically induced fibrosarcoma. They show, in addition, that passively transferred immune cells are capable of destroying already seeded metastases in T cell-deficient recipients.

摘要

P815肥大细胞瘤在半同基因小鼠体内的渐进性生长引发了一种T细胞介导的免疫抑制机制,该机制抑制了被动转移的、肿瘤致敏的T细胞在受体小鼠体内使这种肿瘤消退的能力。这一结论基于两项发现:(a)有可能证明过继性T细胞介导的已建立肿瘤的消退,但前提是肿瘤在T细胞缺陷的受体中生长;(b)在这些受体中,过继性T细胞介导的肿瘤消退可被来自T细胞完整、荷瘤供体的脾T细胞输注所抑制。旨在测量减少抑制细胞数量及其输注时间对相关免疫细胞影响的额外实验结果表明,该模型中抑制细胞的功能是抑制被动转移的免疫T细胞的复制。用P815肥大细胞瘤获得的结果与先前用化学诱导的纤维肉瘤获得的结果相似。此外,它们还表明,被动转移的免疫细胞能够在T细胞缺陷的受体中破坏已经接种的转移瘤。